



Social Purpose Report 2022

2022 is the second year of Ice Bear Therapeutics' existence with the mission to bring affordable insulin therapies to the market. Two insulins are planned to be produced; a short- and a long-acting insulin. Both, short- and long-acting insulins are required in most cases to successfully manage blood glucose in patients with diabetes.

To achieve the goal of affordable insulin therapies, Ice Bear Therapeutics has developed a novel approach to manufacturing insulins. This process is more efficient, faster, requires less space, can be fully automated and has been filed for a provisional patent in 2022. R&D to manufacture short-acting insulin have been concluded, while long-acting insulin manufacturing still has room for improvements. We have outlined strategies to take advantage of optimization potential that are ready to be tested. Ice Bear Therapeutics is in negotiations with research institutes to facilitate these experiments. Next steps are to conclude R&D on the long-acting insulin manufacturing, upscale process for commercial production and finalize patent application in 2023.

Demonstrating the importance of the mission to bring affordable insulins to the market and the novelty and potential of the new technology, Ice Bear Therapeutics has been invited to join the Life Science Washington Institute (LSWI). Here, life science entrepreneurs are supported through educational and economic programs and are connected with investors and partners to succeed on their ventures.

We continue to look for investors and partners to achieve our mission to bring affordable insulins to patients with diabetes.

Sincerely,

Christian Pflieger, PhD

Co-founder, CEO



Ice Bear Therapeutics SPC
9030A 17th Ave SW
Seattle, WA 98106